Anti-CD3 microporous annealed particle hydrogel protects stem cell derived beta cells from autoreactive T cells.

ABSTRACT: Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells, leaving patients dependent on exogenous insulin and at risk of severe hypoglycemic episodes. Stem cell-derived beta-like cells (sBCs) offer a promising approach for beta cell replacement therapy, but clinical translation is limited by immune-mediated rejection, recurrent autoimmunity, and inhospitable transplantation sites. Biomaterials have been investigated to provide localized immune-isolation and immunomodulation, but foreign body responses and rapid depletion of therapeutic agents remain as obstacles to clinical translation. Here, we present a microporous annealed particle (MAP) hydrogel functionalized with an anti-CD3 monoclonal antibody (αCD3) to provide a localized immunomodulatory microenvironment

SUBMITTER: Widener AE 

PROVIDER: S-EPMC12642621 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature